4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment
4D Molecular Therapeutics Inc (NASDAQ:FDMT) said that in June, the company filed a protocol amendment with the FDA for the ongoing…
Daiichi-AstraZeneca’s Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
The FDA has approved Daiichi Sankyo (OTC:DSNKY) and AstraZeneca plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer (NSCLC)…
Pfizer Announces Top-Line Results From Phase 3 Study Of 20-Valent Pneumococcal Conjugate Vaccine In Infants; Says 20vPnC Demonstrated Favorable Safety And Tolerability Profile
Pivotal top-line data demonstrate a four-dose series of 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, would provide the broadest serotype coverage of any pneumococcal conjugate vaccine in
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…
Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke
Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar
aTyr Pharma Shares Ascend As FDA Grants Fast Track Status To Lung Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease.
Bionano Genomics Announces First Publication Using OGM For Detection Of Repeat Expansions In CANVAS And Adult-Onset Ataxia
ionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) in the analysis of repeat expansion disorders. Repeat expansion disorders are
Menarini Group’s Elacestrant Granted Priority Review By The U.S. FDA For Patients With ER+/HER2- Advanced Or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…
ReShape Lifesciences’ GIBI HD Calibration Tubes Scores FDA Approval For Tummy Tuck Procedures
ReShape Lifesciences Inc (NASDAQ:RSLS) has received FDA 510(k) clearance for the disposable Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for…